RxDoctor Payments Data

Anne Lise Armstrong, MD

Internal Medicine · Meadville, PANPI 1083906119

Payments from drug & device makers

$2,034in general payments, 2019–2025

Across 115 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$413
  • Lilly USA, LLC$293
  • Merck$236
  • Astellas Pharma US Inc$158
  • GSK$142
  • Novartis$129
  • plus $663 from 14 others

What the payments were for

  • Food & beverage$2,02299%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,034 in reported general payments places this provider in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$75,057
Medicare patients
230
Services billed
777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban111$108,403
OzempicSemaglutide88$96,000
JardianceEmpagliflozin129$94,995
XareltoRivaroxaban79$71,303
TrulicityDulaglutide63$60,470
MounjaroTirzepatide25$29,456
RybelsusSemaglutide15$27,479
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$24,893
MyrbetriqMirabegron81$24,683
Repatha SureclickEvolocumab16$8,561
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$5,101
Levothyroxine Sodium369$4,262
SynthroidLevothyroxine Sodium38$3,280
Atorvastatin Calcium398$3,125
Pantoprazole Sodium211$2,248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$413$123,479103 claims
PfizerEliquis$27$108,403111 claims
Lilly USA, LLCTrulicity, Mounjaro$293$89,92688 claims
Johnson & JohnsonXarelto$33$71,30379 claims
GSKTrelegy Ellipta, Arnuity Ellipta$142$27,03048 claims
Astellas Pharma US IncMyrbetriq$158$24,68381 claims
AbbVieSynthroid$100$3,28038 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Meadville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →